Ausgabe 9/2019
Inhalt (12 Artikel)
Calculation of the Coefficient of Variation of Log-Normally Distributed Parameter Values
Johannes H. Proost
Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis
Ahmed Aliyu Abulfathi, Eric H. Decloedt, Elin M. Svensson, Andreas H. Diacon, Peter Donald, Helmuth Reuter
Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
Sven Wind, Ulrike Schmid, Matthias Freiwald, Kristell Marzin, Ralf Lotz, Thomas Ebner, Peter Stopfer, Claudia Dallinger
Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug–Drug Interactions with Potential Perpetrator Drugs
Gerd Mikus, Kathrin I. Foerster, Marlene Schaumaeker, Marie-Louise Lehmann, Jürgen Burhenne, Walter E. Haefeli
Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment
Christian Rolfo, Judith de Vos-Geelen, Nicolas Isambert, L. Rhoda Molife, Jan H. M. Schellens, Jacques De Grève, Luc Dirix, Peter Grundtvig-Sørensen, Guy Jerusalem, Karin Leunen, Morten Mau-Sørensen, Ruth Plummer, Maria Learoyd, Wendy Bannister, Anitra Fielding, Alain Ravaud
Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis
Amit Taneja, Julie Desrivot, Paul Matthias Diderichsen, Roland Blanqué, Lisa Allamasey, Liesbeth Fagard, Ann Fieuw, Ellen Van der Aar, Florence Namour
Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects
Tine A. Bækdal, Jeanett Borregaard, Cilie W. Hansen, Mette Thomsen, Thomas W. Anderson
Assessment of Drug–Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials
Katrijn Bogman, Jochen Brumm, Carsten Hofmann, Mylène Giraudon, Markus Niggli, Carolina Sturm-Pellanda, Annette Sauter, Stefan Sturm, Bernhard Mangold, Christophe Schmitt
Comment on: “Clinical Pharmacokinetics of Atypical Antipsychotics: An Update”
Antonia Periclou, Todd Riccobene, Margit Kapás, István Laszlovszky
Reply to Periclou et al.: “Clinical Pharmacokinetics of Atypical Antipsychotics: An Update”
Massimo Carlo Mauri
Correction to: Clinical Pharmacokinetics of Atypical Antipsychotics: An Update
Massimo Carlo Mauri, Silvia Paletta, Chiara Di Pace, Alessandra Reggiori, Giovanna Cirnigliaro, Isabel Valli, Alfredo Carlo Altamura